Thuy Nguyen1, Barbara Andraka-Christou2, Kosali Simon3, W David Bradford4. 1. O'Neill School of Public and Environmental Affairs, Indiana University, 1315 East Tenth Street, Bloomington, IN 47405, United States of America. Electronic address: thdnguye@indiana.edu. 2. Department of Health Management & Informatics, University of Central Florida, 4000 Central Florida Blvd, Orlando, FL 32816, United States of America. Electronic address: barbara.andraka@ucf.edu. 3. O'Neill School of Public and Environmental Affairs, Indiana University, 1315 East Tenth Street, Bloomington, IN 47405, United States of America; NBER, 1050 Massachusetts Ave, Cambridge, MA 02138, United States of America. Electronic address: simonkos@indiana.edu. 4. Department of Public Administration and Policy, University of Georgia, 201C Baldwin Hall, Athens, GA 30602, United States of America. Electronic address: bradfowd@uga.edu.
Abstract
BACKGROUND: Opioid use disorder (OUD) has become an increasingly grave public health concern, especially in the United States where approximately 80% of the global opioid supply is consumed. Despite greater awareness of the present overdose crisis, potentially life-saving OUD pharmacotherapy (medications for opioid use disorder or MOUD) utilization remains low. This study examines the extent of provider-directed marketing (detailing) for MOUD drugs and identifies any associations between a provider's receipt of detailing and their prescribing of MOUD drugs to Medicare Part D beneficiaries. METHOD: We combined Open Payments data on all provider-directed payments from pharmaceutical manufacturers with physician-level data on all MOUD prescriptions filled in Medicare Part D. We estimated the adjusted difference in Medicare days supply for all MOUD drugs (collectively) and separately for each MOUD drug that was associated with receipt of payments. RESULTS: The Open Payments data show that $7.0 million MOUD-specific promotional payments were made by pharmaceutical manufacturers to 12,056 US physicians from 2014 to 2016, which is <1/6th of the $50.3 million made in overall non-MOUD opioid-related promotional payments to 76,992 US physicians during that same period. Prescribers who received any MOUD-specific payments prescribed 1080 daily MOUD-related doses per year more than peers who did not receive any MOUD-specific payments (p < 0.001). The data also show the relatively greater association between receipt of detailing and Suboxone prescriptions compared to Vivitrol. CONCLUSIONS: Provider-directed marketing by MOUD manufacturers has been found to be significantly and positively associated with incidence of MOUD prescribing in Medicare Part D, as well as with the quantity of MOUD prescribed.
BACKGROUND:Opioid use disorder (OUD) has become an increasingly grave public health concern, especially in the United States where approximately 80% of the global opioid supply is consumed. Despite greater awareness of the present overdose crisis, potentially life-saving OUD pharmacotherapy (medications for opioid use disorder or MOUD) utilization remains low. This study examines the extent of provider-directed marketing (detailing) for MOUD drugs and identifies any associations between a provider's receipt of detailing and their prescribing of MOUD drugs to Medicare Part D beneficiaries. METHOD: We combined Open Payments data on all provider-directed payments from pharmaceutical manufacturers with physician-level data on all MOUD prescriptions filled in Medicare Part D. We estimated the adjusted difference in Medicare days supply for all MOUD drugs (collectively) and separately for each MOUD drug that was associated with receipt of payments. RESULTS: The Open Payments data show that $7.0 million MOUD-specific promotional payments were made by pharmaceutical manufacturers to 12,056 US physicians from 2014 to 2016, which is <1/6th of the $50.3 million made in overall non-MOUD opioid-related promotional payments to 76,992 US physicians during that same period. Prescribers who received any MOUD-specific payments prescribed 1080 daily MOUD-related doses per year more than peers who did not receive any MOUD-specific payments (p < 0.001). The data also show the relatively greater association between receipt of detailing and Suboxone prescriptions compared to Vivitrol. CONCLUSIONS: Provider-directed marketing by MOUD manufacturers has been found to be significantly and positively associated with incidence of MOUD prescribing in Medicare Part D, as well as with the quantity of MOUD prescribed.
Keywords:
Drug prescriptions; Medicare Part D; Medication-assisted treatment; Opioid use disorder; Pharmaceutical payments; Provider-directed marketing
Authors: Lillian Y Lai; Mary K Oerline; Samuel R Kaufman; Lindsey A Herrel; Ted A Skolarus; Stacie B Dusetzina; Chad Ellimoottil; Vahakn B Shahinian; Brent K Hollenbeck; Megan E V Caram Journal: Urology Date: 2021-12-01 Impact factor: 2.649
Authors: Erica Morse; Ingrid A Binswanger; Emmeline Taylor; Caroline Gray; Matthew Stimmel; Christine Timko; Alex H S Harris; David Smelson; Andrea K Finlay Journal: J Subst Abuse Treat Date: 2021-03-04